WEBCAST: The Wait is Over — Now What? Steps to Respond to the Proposed 340B Omnibus Guidance
Webcast
Summary
2:30 – 3:30 pm EDT
To view the archived presentation, please click here.
HHS Releases Long-Awaited 340B Proposed Guidance, On the Subject
The impact of the Proposed Guidance includes the following:
- Significantly revised definitions of
- Drugs eligible for discounted 340B prices and
- Patients eligible to receive such discounts
- Future alterations including compliance with the group purchasing organization (GPO) prohibition, contracts with governmental entities to support 340B Program eligibility, auditable records requirements, dispensing of 340B drugs to Medicaid managed care enrollees, and contract pharmacy oversight, among other topics
The webcast will focus on the implications to the 340B Program if the Proposed Guidance is implemented as proposed and how to respond to the Proposed Guidance.
McDermott Speakers
Emily J. Cook, Partner
David S. Ivill, Partner
Joseph M. Parise, Associate
Moderator
Jason B. Caron, Partner
For more information, please contact McDermott Events.
CLE credit for the live presentation of this program is pending in the following states: California, Illinois, New York and Texas. A Uniform Certificate of Attendance will be made available to participants requesting CLE credit in all other states. Please be advised that CLE credit will not be approved for on demand/recorded viewings of this program in the states listed above. Attendees seeking credit in other states should consult their state CLE accrediting agency to determine whether self-study credit can be earned for on demand/recorded viewing of this program.